Validation of the GALAD model and establishment of a new model for HCC detection in Chinese patients

Background GALAD model is a statistical model used to estimate the possibility of hepatocellular carcinoma (HCC) in patients with chronic liver disease. Many studies with other ethnic populations have shown that it has high sensitivity and specificity. However, whether this model can be used for Chinese patients remains to be determined. Our study was conducted to verify the performance of GALAD model in a Chinese cohort and construct a new model that is more appropriately for Chinese populations. Methods There are total 512 patients enrolled in the study, which can be divided into training set and validation set. 80 patients with primary liver cancer, 139 patients with chronic liver disease and 87 healthy people were included in the training set. Through the ROC(receiver operating characteristic) curve analysis, the recognition performance of GALAD model for liver cancer was evaluated, and the GAADPB model was established by logistic regression, including gender, age, AFP, DCP, total protein, and total bilirubin. The validation set (75 HCC patients and 130 CLD patients) was used to evaluate the performance of the GAADPB model. Result The GALAD and GAADPB achieved excellent performance (area under the receiver operating characteristic curve [AUC], 0.925, 0.945), and were better than GAAP, Doylestown, BALAD-2, aMAP, AFP, AFP-L3%, DCP and combined detection of AFP, AFP-L3 and DCP (AUCs: 0.894, 0.870, 0.648, 0.545, 0.879, 0.782, 0.820 and 0.911) for detecting HCC from CLD in the training set. As for early stage of HCC (BCLC 0/A), GAADPB had the best sensitivity compared to GALAD, ADP and DCP (56.3%, 53.1%, 40.6%, 50.0%). GAADPB had better performance than GALAD in the test set, AUC (0.896 vs 0.888). Conclusions The new GAADPB model was powerful and stable, with better performance than the GALAD and other models, and it also was promising in the area of HCC prognosis prediction. Further study on the real-world HCC patients in China are needed.

[1]  J. Marrero,et al.  GALAD demonstrates high sensitivity for HCC surveillance in a cohort of patients with cirrhosis , 2021, Hepatology.

[2]  N. Chalasani,et al.  Validation of a novel multi-target blood test shows high sensitivity to detect early-stage hepatocellular carcinoma. , 2021, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[3]  A. Jemal,et al.  Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries , 2021, CA: a cancer journal for clinicians.

[4]  Xinyuan Zhang,et al.  Prediction of late recurrence after radiofrequency ablation of HBV-related hepatocellular carcinoma with the age-male-albumin-bilirubin-platelets (aMAP) risk score: a multicenter study. , 2021, Journal of gastrointestinal oncology.

[5]  J. Niu,et al.  Validation of the GALAD Model and Establishment of GAAP Model for Diagnosis of Hepatocellular Carcinoma in Chinese Patients , 2020, Journal of hepatocellular carcinoma.

[6]  N. Chalasani,et al.  A Novel Blood-based Panel of Methylated DNA and Protein Markers for Detection of Early-Stage Hepatocellular Carcinoma. , 2020, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[7]  R. Salgia,et al.  The Changing Global Epidemiology of Hepatocellular Carcinoma. , 2020, Clinics in liver disease.

[8]  M. Buti,et al.  aMAP risk score predicts hepatocellular carcinoma development in patients with chronic hepatitis. , 2020, Journal of hepatology.

[9]  Erratum: Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. , 2020, CA: a cancer journal for clinicians.

[10]  T. Berg,et al.  GALAD Score Detects Early Hepatocellular Carcinoma in an International Cohort of Patients With Nonalcoholic Steatohepatitis. , 2019, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[11]  T. Murakami,et al.  Clinical practice guidelines for hepatocellular carcinoma: The Japan Society of Hepatology 2017 (4th JSH‐HCC guidelines) 2019 update , 2019, Hepatology research : the official journal of the Japan Society of Hepatology.

[12]  A. Villanueva Hepatocellular Carcinoma. , 2019, The New England journal of medicine.

[13]  G. Gores,et al.  GALAD Score for Hepatocellular Carcinoma Detection in Comparison with Liver Ultrasound and Proposal of GALADUS Score , 2018, Cancer Epidemiology, Biomarkers & Prevention.

[14]  Jinzhou Zhu,et al.  Epidemiological Trends in Gastrointestinal Cancers in China: An Ecological Study , 2018, Digestive Diseases and Sciences.

[15]  J. Marrero,et al.  Surveillance Imaging and Alpha Fetoprotein for Early Detection of Hepatocellular Carcinoma in Patients With Cirrhosis: A Meta-analysis. , 2018, Gastroenterology.

[16]  J. Bruix,et al.  Hepatocellular carcinoma , 2018, The Lancet.

[17]  T. Therneau,et al.  Model combining pre-transplant tumor biomarkers and tumor size shows more utility in predicting hepatocellular carcinoma recurrence and survival than the BALAD models , 2018, World journal of gastroenterology.

[18]  M. Manns,et al.  Role of the GALAD and BALAD-2 Serologic Models in Diagnosis of Hepatocellular Carcinoma and Prediction of Survival in Patients. , 2016, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[19]  Ziding,et al.  The Doylestown algorithm – a test to improve the performance of AFP in the detection of hepatocellular carcinoma , 2015 .

[20]  K. McGlynn,et al.  Global epidemiology of hepatocellular carcinoma: an emphasis on demographic and regional variability. , 2015, Clinics in liver disease.

[21]  S. Berhane,et al.  Biomarker-based prognosis in hepatocellular carcinoma: validation and extension of the BALAD model , 2014, British Journal of Cancer.

[22]  P. Johnson,et al.  P554 ASSESSMENT OF PROGNOSIS IN HEPATOCELLULAR CARCINOMA USING A BIOMARKER BASED APPROACH: VALIDATION AND EXTENSION OF THE BALAD MODEL , 2014 .

[23]  H. Reeves,et al.  The Detection of Hepatocellular Carcinoma Using a Prospectively Developed and Validated Model Based on Serological Biomarkers , 2013, Cancer Epidemiology, Biomarkers & Prevention.

[24]  F. Schmidt Meta-Analysis , 2008 .

[25]  M. Kudo,et al.  Staging hepatocellular carcinoma by a novel scoring system (BALAD score) based on serum markers. , 2006, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[26]  L. Webb,et al.  An ecological study. , 1979, Science.